SFTPA2 and asthma: Seventy-five participants with mild-moderate asthma (FEV1: 87 ± 2% predicted), and sixty-eight non-asthmatic participants (FEV1: 100 ± 2% predicted) underwent blood sampling for gene sequencing of the SP-A2 gene (Table 1).